BYSI News and Press, BeyondSpring Inc. From 12/15/20

BYSI's lead candidate plinabulin in combo with Neulasta reduces grade 4 neutropenia in chemo patients better than Neulasta alone. However, the company is in perpetual cash-hungry mode, and every time it raises cash, the stock suffers. Catalysts are about a year ahead, but dilution...

- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone - The plinabulin + pegfilgrastim combination reduces the odds of having febrile neutropenia by 41% vs. pegfilg...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 10:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The major stock market averages all closed up more than 2% for the holiday-shortened week, as an early recovery-play rally gave way to a tech-safety trade...

B eyondSpring to present at the 62nd American Society of Hematology (ASH) Annual Meeting and at the 2020 San Antonio Breast Cancer Symposium NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “...

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medi...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks ended lower on Friday on raised concerns over the economic impact of the pandemic and the Treasury Department's new curtailing of emergency economic...

X Financial (XYF) -33%.MeiraGTx Holdings (MGTX) -10% on public offering pricing at $12.85/share.Tantech Holdings (TANH) -9%.BeyondSpring (BYSI) -9% on public offering pricing at $10.0/share.Chindata Group Holdings (CD) -7% on Q3 earnings release.Phoenix Tree Hold...

BeyondSpring (BYSI) slips 9% premarket, after pricing its previously announced public offering of 7.5M shares at $10.0/share, for gross proceeds of ~$75M.The offering is expected to close by November 23. For further details see: BeyondSpring slides 9% on public offering pricing at $10.0...

BeyondSpring (BYSI) -3.5% AH, launched an underwritten public offering of $75M; underwriters granted an option to purchase up to an additional $11.25M shares.Proceeds to be used for supporting the commercialization of Plinabulin, continued clinical and pre-clinical development and for ge...

BeyondSpring (BYSI): Q3 GAAP EPS of -$0.48 beats by $0.06.Cash and cash equivalents of $30.87M.Press Release For further details see: BeyondSpring EPS beats by $0.06